Alcon introduces its next-generation trifocal IOL; Alcon announces a deal to advance its clinical-stage allogeneic cell therapy; and Bausch + Lomb announces a voluntary recall of IOLs on its enVista platform.
Learn more about your ad choices. Visit megaphone.fm/adchoices
